Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA's Gottlieb Shuts The Door On Exclusivity For 'Transition' Biologics

Dec 11 2018

• By Michael Cipriano

Women hand close door knob or close the door.

Related Content

REMS Abuse Website: All Sizzle, No Steak?

Sep 06 2018

BLAs More Appealing As 'Transition' NDAs, ANDAs Set To Lose Exclusivity

Mar 21 2016

FDA Biologic Transition Plan Creates 'Dead Zone' For Applications, Sponsors Fear

May 23 2016

Gottlieb: Real Risk Of Congressional Action If Anti-Competitive Actions Continue

May 04 2018

REMS Abuse Website: Celgene, Actelion Top List Of Suspected 'Gamers'

May 18 2018

Related Companies

Eli Lilly and Company

Novo Nordisk A/S

Sanofi

Additional Topics

United States Biosimilars Biologics Regulation BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window